Longboard Pharmaceuticals Inc (LBPH)

Nov 12, 2024, 8:30 AM EST - 2 months ago

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Nov 7, 2024, 4:01 PM EST - 2 months ago

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Oct 31, 2024, 12:03 PM EDT - 3 months ago

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

Oct 17, 2024, 5:45 PM EDT - 3 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders

ARC

Oct 15, 2024, 6:47 PM EDT - 3 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and OB on Behalf of Shareholders

OB

Oct 14, 2024, 5:47 PM EDT - 3 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.

Oct 14, 2024, 3:06 PM EDT - 3 months ago

Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump

Oct 14, 2024, 2:29 PM EDT - 3 months ago

S&P 500 hits record high; Dow gains as Longboard Pharmaceuticals surges 51% and tech stocks rise

Oct 14, 2024, 10:50 AM EDT - 3 months ago

Longboard Pharmaceuticals' stock soars amid Lundbeck's $2.6 billion deal to acquire the company

Oct 14, 2024, 8:13 AM EDT - 3 months ago

Longboard Pharmaceutical Stock Soars 51%. It's Being Bought for $2.6 Billion.

Oct 14, 2024, 6:39 AM EDT - 3 months ago

Lundbeck to buy Longboard Pharma in $2.6 billion deal

Oct 14, 2024, 6:30 AM EDT - 3 months ago

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

Oct 4, 2024, 4:01 PM EDT - 4 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Sep 26, 2024, 8:30 AM EDT - 4 months ago

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

Sep 19, 2024, 8:30 AM EDT - 4 months ago

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

Sep 8, 2024, 6:30 AM EDT - 5 months ago

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Aug 28, 2024, 4:00 PM EDT - 5 months ago

Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September

Aug 28, 2024, 8:00 AM EDT - 5 months ago

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 26, 2024, 4:01 PM EDT - 5 months ago

Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress

Aug 26, 2024, 9:00 AM EDT - 5 months ago

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024

Aug 4, 2024, 1:39 PM EDT - 6 months ago

Longboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:01 PM EDT - 6 months ago

Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jul 29, 2024, 9:15 AM EDT - 6 months ago

Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1

Jul 3, 2024, 9:41 AM EDT - 7 months ago

Top 3 Health Care Stocks That May Crash This Quarter

HROW LLY

Jul 1, 2024, 9:00 AM EDT - 7 months ago

Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Jun 10, 2024, 9:00 AM EDT - 8 months ago

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

May 2, 2024, 4:01 PM EDT - 9 months ago

Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 3, 2024, 9:00 AM EDT - 10 months ago

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

Mar 12, 2024, 4:01 PM EDT - 11 months ago

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Feb 1, 2024, 8:30 AM EST - 1 year ago

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

Jan 8, 2024, 4:05 PM EST - 1 year ago

Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 3, 2024, 9:40 PM EST - 1 year ago

Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 2, 2024, 4:01 PM EST - 1 year ago

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Jan 2, 2024, 8:00 AM EST - 1 year ago

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Jan 1, 2024, 4:47 PM EST - 1 year ago

Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Nov 29, 2023, 8:30 AM EST - 1 year ago

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Nov 21, 2023, 4:00 PM EST - 1 year ago

Longboard Pharmaceuticals' Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Nov 3, 2023, 4:01 PM EDT - 1 year ago

Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 2, 2023, 4:01 PM EDT - 1 year ago

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 8:30 AM EDT - 1 year ago

Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November

Oct 5, 2023, 4:05 PM EDT - 1 year ago

Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023

Sep 19, 2023, 8:30 AM EDT - 1 year ago

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023

Aug 31, 2023, 4:00 PM EDT - 1 year ago

Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences

Aug 30, 2023, 4:01 PM EDT - 1 year ago

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

Aug 23, 2023, 8:30 AM EDT - 1 year ago

Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

Aug 3, 2023, 4:01 PM EDT - 1 year ago

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 8:30 AM EDT - 1 year ago

Longboard Pharmaceuticals to Present at Upcoming Investor Conferences

Jun 26, 2023, 4:00 PM EDT - 1 year ago

Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023